On this World Cancer Day, we stand United By Unique, recognizing the personal journeys of those impacted by cancer and advocating for more people-centered care. At Asphalion, we are proud to contribute to the fight against cancer through regulatory expertise, ensuring the safe and efficient development of innovative therapies.
As part of the EU-funded PragmaTIL project, we are leading the regulatory activities, including the clinical trial submission and safety management plan. The PragmaTIL project focuses on optimizing Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) to enhance cancer treatment in academic hospitals. By reducing the treatment-related toxicities of high-dose interleukin-2 (HD-IL-2) while maintaining efficacy, PragmaTIL aims to improve patient outcomes and expand clinical implementation.
Learn more about PragmaTIL: www.pragmatil.eu
Contact us at: [email protected]
Together, let’s close the care gap and make personalized cancer therapies more accessible!
